Evidence map›Paper›PMID 32430845›Full record

ArticleMolecular biology reports2020

MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers.

Mohammed Elhendawy, Enas A Abdul-Baki, Sherief Abd-Elsalam, Maha M Hagras, Abdul-Aziz Zidan, Amira Y Abdel-Naby, Mona Watny, Ibrahem Ali Elkabash, Mohamed Labib Salem, Mohamed Elshanshoury and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Dynamic evolution and antitumor mechanisms of CXCR6Journal of translational medicine · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mohammed ElhendawyDepartment of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, El-Giash Street, Tanta, 31527, Egypt.
Enas A Abdul-BakiPhysiology Department, Faculty of Science, Tanta University, Tanta, Egypt.
Sherief Abd-ElsalamDepartment of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, El-Giash Street, Tanta, 31527, Egypt. sherif.abdelbaky@med.tanta.edu.ed.ORCID http://orcid.org/0000-0003-4366-2218
Maha M HagrasClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Abdul-Aziz ZidanImmunology & Physiology Department, Faculty of Science, Damanhour University, Damanhour, Egypt.
Amira Y Abdel-NabyClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mona WatnyClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Ibrahem Ali ElkabashPublic Health & Community Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed Labib SalemImmunology Department, Faculty of Science, Tanta University, Tanta, Egypt.
Mohamed ElshanshouryPediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Shaimaa SolimanPublic Health & Community Medicine Department, Faculty of Medicine, Menoufia University, Shibin el Kom, Egypt.
Said AbdouClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Tanta University · EGDamanhour University · EGMenoufia University · EGTanta University Hospital · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) play important roles in liver pathologies and they are potential biomarkers for diagnosis of liver diseases progression. Changes in miRNA sera expression can be used as non-invasive biomarkers for hepatocellular carcinoma (HCC). The aim of the study was to identify the miRNome profiling of HCC and its diagnostic value in distinguishing HCC from healthy individuals. Expression profiles of miRNAs in serum samples of 20 HCC patients and 10 healthy controls were detected. Whole miRNome profiling was done using next generation sequencing. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic performance of the deregulated miRNAs for discriminating HCC cases from healthy controls. MiRNA 142 was highly expressed in HCC (P value = 0.023) while miRNAs 191, 22, and 126 were higher in the controls (P value = 0.005, 0.034, 0.010 respectively). We have identified 5 novel miRNAs and they were highly expressed in HCC than controls. Analysis of ROC curve demonstrated that these deregulated miRNAs can be used as a reliable biomarker for detection of HCC with high diagnostic accuracy (AUC = 0.93). We have detected a panel of serum miRNAs that can be used as a reliable noninvasive screening biomarker of HCC. The study recommends further research to shed light on a possible role of the newly discovered novel miRNAs in HCC pathogenesis.

Indexed as

AgedBiomarkers, TumorCarcinoma, HepatocellularCirculating MicroRNAFemaleHumansLiver NeoplasmsMaleMiddle AgedBiomarkers, TumorCirculating MicroRNAEgyptGeneHCCHepatitis C virusMarkerTumors

Identifiers

PMID32430845
OpenAlexW3028279047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.